Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 26, 2021; 9(30): 9134-9143
Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.9134
Long-term survival of a patient with pancreatic cancer and lung metastasis: A case report and review of literature
Wen-Wei Yang, Lin Yang, Hai-Zhen Lu, Yong-Kun Sun
Wen-Wei Yang, Lin Yang, Yong-Kun Sun, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Hai-Zhen Lu, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Author contributions: Yang WW contributed to the composition of the manuscript and literature review; Sun YK and Yang L contributed to patient treatment and evaluation; Lu HZ analyzed the pathological subtype of tumor tissues; Sun YK supported final approval of the paper; All authors contributed to manuscript revision, read and approved the final version.
Supported by Wu Jieping Medical Foundation, No. 320.6750.2020-10-95; and Sanming Project of Medicine in Shenzhen, No. SZSM202011010.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflicting interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Kun Sun, MD, Professor, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. hsunyk@cicams.ac.cn
Received: March 22, 2021
Peer-review started: March 22, 2021
First decision: July 5, 2021
Revised: July 13, 2021
Accepted: August 13, 2021
Article in press: August 13, 2021
Published online: October 26, 2021
Processing time: 213 Days and 2.5 Hours
Core Tip

Core Tip: We report a patient with pancreatic ductal adenocarcinoma (PDAC) possessing exceptionally rare RAF1, BAP1 and PIK3CA gene alterations who achieved partial response to apatinib combination therapy twice and experienced long-term survival. Until now, there have been no reports of a long-term PDAC patient with RAF1, BAP1 and PIK3CA aberrations who did not also have K-Ras, TP53, p16/ CDKN2A, or SMAD4 gene alterations. In such a rare case, we presume that PDAC with this special genetic alteration pattern might be converted to a kind of indolent cancer, which presents fewer symptoms and indicates a good prognosis for pancreatic cancer patients.